We are live on ! Find out more
WHWK

Whitehawk Therapeutics

65 hedge funds and large institutions have $26.8M invested in Whitehawk Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 25 increasing their positions, 11 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 11

47% more call options, than puts

Call options by funds: $25K | Put options by funds: $17K

5.89% less ownership

Funds ownership: 60.06%54.16% (-5.9%)

11% less funds holding

Funds holding: 7365 (-8)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

37% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 19

64% less capital invested

Capital invested by funds: $75.3M → $26.8M (-$48.4M)

Holders
65
Holders Change
-8
Holders Change %
-10.96%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
12
Increased
25
Reduced
11
Closed
19
Calls
$25K
Puts
$17K
Net Calls
+$8K
Net Calls Change
-$62K
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$5.76M
ACP
2
Acuta Capital Partners
California
$3.74M
AIM
3
Alerce Investment Management
Illinois
$3.29M
BlackRock
4
BlackRock
New York
$2.18M +$318K +75,825 +8%
Morgan Stanley
5
Morgan Stanley
New York
$2.06M +$3.37M +802,199 +366%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.74M +$371K +88,313 +11%
DC
7
Decheng Capital
California
$1.06M +$2.21M +526,329 New
VC
8
Vivo Capital
California
$1.03M
Citadel Advisors
9
Citadel Advisors
Florida
$824K +$719K +171,456 +73%
Renaissance Technologies
10
Renaissance Technologies
New York
$805K +$641K +152,800 +62%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$800K +$122K +29,079 +8%
State Street
12
State Street
Massachusetts
$636K +$77.8K +18,540 +6%
BBA
13
Baker Bros. Advisors
New York
$508K -$3.1M -738,201 -75%
6CM
14
683 Capital Management
New York
$404K +$839K +200,000 New
Northern Trust
15
Northern Trust
Illinois
$328K +$89K +21,215 +15%
Ameriprise
16
Ameriprise
Minnesota
$209K -$201K -47,819 -32%
LPC
17
Lion Point Capital
New York
$166K
Bank of New York Mellon
18
Bank of New York Mellon
New York
$101K +$3.42K +815 +2%
Squarepoint
19
Squarepoint
New York
$93.3K +$94.7K +22,565 +96%
Charles Schwab
20
Charles Schwab
California
$91.6K
SSA
21
Schonfeld Strategic Advisors
New York
$84.2K +$11.3K +2,700 +7%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$72K -$65.7K -15,660 -31%
Bank of America
23
Bank of America
North Carolina
$63.7K +$48.1K +11,455 +57%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$63.5K +$75.1K +17,905 +132%
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$62.4K +$130K +30,877 New

WHWK Hedge Fund Activity: Q4 2023 in Review

65 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2023, worth a combined $26.8M — down 64% from $75.3M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of WHWK and 12 opened new positions — a net loss of 7 holders — while 11 trimmed existing stakes and 25 added.

The largest buyer was Morgan Stanley, adding an estimated $3.37M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $3.78M sold.

  • 65 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2023, down from 73 in Q3 2023.
  • Funds reported $26.8M of Whitehawk Therapeutics stock for Q4 2023, down 64% quarter-over-quarter.
  • 12 funds opened new Whitehawk Therapeutics positions in Q4 2023 and 19 closed out, a net change of -7 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $3.37M added.
  • The largest Whitehawk Therapeutics seller in Q4 2023 was Janus Henderson Group, an estimated $3.78M sold.

Based on aggregated 13F filings for Q4 2023.